In re Xyrem (Sodium Oxybate) Antitrust Litigation
Case Number:
3:20-md-02966
See also:
Court:
Nature of Suit:
Multi Party Litigation:
Class Action, Multi-district Litigation
Judge:
Firms
- Barnes & Thornburg
- Benesch
- Berger Montague
- Boies Schiller
- DiCello Levitt
- Faegre Drinker
- Fine Kaplan
- Frost Brown
- Gibson Dunn
- Girard Sharp
- Goodwin Procter
- Hagens Berman
- Holland & Knight
- Husch Blackwell
- Joseph Saveri Law Firm
- Kirkland & Ellis
- Labaton Keller
- Law Offices of Robert W. Sink
- Lowey Dannenberg
- Motley Rice
- O'Melveny & Myers
- Paul Hastings
- Radice Law Firm
- Rawlings & Associates PLLC
- Salahi PC
- Schneider Wallace
- Schneider Wallace Cottrell Konecky LLP
- Scott&Scott
- Skaggs Faucette
- Spector Roseman
- Spiro Harrison
- Steven Williams Law
- Troutman
- Weil Gotshal
- Wexler Boley
- White & Case
- Williams & Connolly
- Wilson Sonsini
- Winston & Strawn
- Zelle LLP
- Zimmerman Reed
Companies
- Aetna Inc.
- Amneal Pharmaceuticals Inc.
- Blue Cross Blue Shield Association
- Endo International PLC
- Express Scripts Holding Co.
- Florida Blue
- Government Employees Health Association Inc.
- Health Care Service Corp.
- Hikma Pharmaceuticals PLC
- Humana Inc.
- Jazz Pharmaceuticals Inc.
- Lupin Ltd.
- Mallinckrodt PLC
- Molina Healthcare Inc.
- Par Pharmaceutical Cos. Inc.
- Ranbaxy
- Teva Pharmaceutical Industries Ltd.
- United Food & Commercial Workers International Union
- Veranova LP
- West-Ward Pharmaceutical Corp.
- Wockhardt USA LLC
Sectors & Industries:
-
April 08, 2025
Jazz Agrees To Pay $145M To Settle Xyrem Antitrust Fight
Jazz Pharmaceuticals has agreed to pay $145 million to resolve antitrust litigation accusing it of working with its rival Hikma Pharmaceuticals to stave off generic competitors to Jazz's narcolepsy drug Xyrem, the Ireland-based pharmaceutical company revealed Tuesday.
-
March 17, 2025
Jazz Inks Insurer Class Deal As Xyrem Antitrust Trial Nears
Jazz Pharmaceuticals and a certified insurer class told a California federal judge Monday that they have reached a settlement-in-principle in antitrust litigation accusing Jazz of working with pharma rival Hikma to block generic competitors to Jazz's narcolepsy drug, while two opt-out insurer plaintiffs and defendant Hikma have not reached any deals ahead of a May trial.
-
August 28, 2024
Jazz, Hikma Must Face Bulk Of Xyrem Antitrust Suit
Jazz Pharmaceuticals and Hikma Pharmaceuticals appear bound for trial against most solo insurer and class action antitrust claims over alleged efforts to block generic competitors to Jazz's Xyrem narcolepsy drug, under a newly unsealed California federal court order largely rejecting competing motions for summary judgment.
-
July 19, 2024
Jazz Says Narcolepsy Drug Charge MDL Should Be Tossed
Jazz Pharmaceuticals urged a California federal judge to toss claims from insurers and consumers pursuing multidistrict litigation accusing the drugmaker of staving off generic competition to its blockbuster narcolepsy medicine Xyrem through antitrust conduct and deals with other drugmakers, saying the company engaged in "permissible competition."
-
November 16, 2023
Illinois Seeks To Rejoin Narcolepsy Drug Overcharge Suit
Illinois is looking for a way back into an ongoing class action against Jazz Pharmaceuticals, telling the California federal judge presiding over the multidistrict case that another judge's order excluding Illinois insurers who reimbursed patients for the price of narcolepsy drug Xyrem should be reversed.
-
May 16, 2023
Jazz Ducks BCBS Claims But Not Xyrem Class Cert.
A California federal judge granted class certification Friday to insurers and consumers pursuing multidistrict litigation accusing Jazz Pharmaceuticals of staving off generic competition to its blockbuster narcolepsy drug Xyrem through a web of anti-competitive conduct and deals with other drugmakers, even as he nixed Blue Cross Blue Shield claims.